5-MeO-DMT clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a tryptamine found in some plants and in one toad species. This page summarises registered studies whose registry records mention it, using PsychoactiveMap's copy of the ClinicalTrials.gov registry.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 17 registered 5-MeO-DMT studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 6% |
| Active, not recruiting | 1 | 6% |
| Completed | 11 | 65% |
| Terminated | 3 | 18% |
| Withdrawn | 1 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 12 | 71% |
| Phase 2 | 4 | 24% |
| Not reported | 1 | 6% |
Countries
Country is taken from the study's linked research site. 0 of 17 records have no country on file. The top 7 countries are shown.
| Country | Studies | Share |
|---|---|---|
| Netherlands | 5 | 29% |
| United States | 4 | 24% |
| Argentina | 2 | 12% |
| Switzerland | 2 | 12% |
| United Kingdom | 2 | 12% |
| Czechia | 1 | 6% |
| Germany | 1 | 6% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 7 |
| 2020 to 2023 | 8 |
| 2015 to 2019 | 2 |
Study design
- 16 interventional and 1 observational studies.
- Median planned or actual enrolment is 38 participants (range 6 to 81, across 16 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Healthy volunteers | 8 |
| Depression and mood | 6 |
| Anxiety | 2 |
Most recently started studies
The 17 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07540494 | Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | Completed | Phase 1 | United States | 2026-04 |
| NCT07444788 | Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2026-03 |
| NCT06810765 | Trifecta Research Study | Withdrawn | Phase 2 | United States | 2025-09 |
| NCT06812221 | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Completed | Phase 1 | Argentina | 2024-12 |
| NCT06816667 | Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Completed | Phase 1 | Argentina | 2024-10 |
| NCT06511947 | Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects | Terminated | Phase 1 | United Kingdom | 2024-08 |
| NCT06252506 | Molecular Imaging Study of Harmine/DMT: a Basic Research Approach | Completed | Phase 1 | Switzerland | 2024-01 |
| NCT05800860 | A Trial of GH001 in Patients With Treatment-resistant Depression | Completed | Phase 2 | Czechia | 2023-05 |
| NCT05839509 | Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | Terminated | Phase 2 | Germany | 2023-04 |
| NCT05804708 | Phase 2 Clinical Trial of GH001 in Postpartum Depression | Terminated | Phase 2 | Netherlands | 2023-03 |
| NCT05698095 | Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers | Completed | Phase 1 | United States | 2022-12 |
| NCT05753956 | Safety and Pharmacokinetics of GH002 in Healthy Volunteers | Completed | Phase 1 | Netherlands | 2022-12 |
| NCT07717866 | Trifecta Research Study | Active, not recruiting | Not reported | United States | 2022-08 |
| NCT05032833 | Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects | Completed | Phase 1 | United Kingdom | 2021-09 |
| NCT05163691 | Pharmacokinetics of GH001 in Healthy Volunteers | Completed | Phase 1 | Netherlands | 2021-06 |
| NCT04698603 | Clinical Study of GH001 in Depression | Completed | Phase 1 | Netherlands | 2019-11 |
| NCT04640831 | Safety of GH001 in Healthy Volunteers | Completed | Phase 1 | Netherlands | 2019-03 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
Psilocybin | MDMA | LSD | DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable